|
Infectious diseases / Review
Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus patients
Jinnam Kim, Choseok Yoon, Bongyoung Kim, Se Yoon Park
Korean J Intern Med. 2026;41(6):1020-1039. Published online November 1, 2026
Pneumocystis jirovecii pneumonia (PJP) is an important opportunistic fungal infection in immunocompromised hosts. Although its incidence has declined markedly in people with human immunodeficiency virus (HIV) following the widespread use of antiretroviral therapy and prophylaxis, PJP is incre..
|
|
|
Gastroenterology / Original Article
Endoscopic features of cytomegalovirus disease of the upper gastrointestinal tract between transplant and non-transplant patients
Yuri Kim, Do Hoon Kim, Myeongsook Seo, Hee Kyong Na, Kee Wook Jung, Ji Yong Ahn, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
Korean J Intern Med. 2025;40(3):394-403. Published online March 25, 2025
Background/Aims: Cytomegalovirus (CMV) disease in the upper gastrointestinal (UGI) tract frequently occurs in immunocompromised patients. However, data regarding UGI CMV disease in non-transplant patients compared with those in transplant recipients are limited. Therefore, we compared the clinical c..
|
|
|
Infectious diseases / Review
Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea
Sung-Yeon Cho, Hyeon-Jeong Lee, Dong-Gun Lee
Korean J Intern Med. 2018;33(2):256-276. Published online February 27, 2018
Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidit..
|
|
|
Infectious diseases / Review
Voriconazole-refractory invasive aspergillosis
Se Yoon Park, Jung-A Yoon, Sung-Han Kim
Korean J Intern Med. 2017;32(5):805-812. Published online August 24, 2017
Invasive aspergillosis (IA) is one of the most common life-threatening complications in immunocompromised patients. Voriconazole is currently the drug of choice for IA treatment. However, some patients with IA suffer clinical deterioration despite voriconazole therapy. Management of voriconazole-ref..
|
|
|
